Vivo Capital, LLC
CIK: 0001674712Latest portfolio: $1.5B · Q4 2025
Holdings
47
Total Value
$1.5B
New Positions
7
Closed Positions
7
Top Holdings
View All 47 Holdings →| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | TERNTerns Pharmaceuticals Inc | 5,346,928 | $216.0M | 13.96% | -1,548,818 | |
| 2 | CDTXCidara Therapeutics, Inc. | 956,670 | $211.3M | 13.66% | -354,755 | |
| 3 | PRAXPraxis Precision Medicines | 328,895 | $96.9M | 6.27% | +130K | |
| 4 | COGTCogent Biosciences Inc | 2,398,993 | $85.2M | 5.51% | -390,144 | |
| 5 | TRVITrevi Therapeutics Inc | 5,094,668 | $63.8M | 4.12% | — | |
| 6 | AVDLAvadel Pharmaceuticals PLC | 2,684,109 | $57.8M | 3.74% | — | |
| 7 | CMPXCompass Therapeutics Inc | 9,545,466 | $51.3M | 3.31% | — | |
| 8 | DYNDyne Therapeutics Inc | 2,614,960 | $51.1M | 3.31% | — | |
| 9 | ABVXAbivax SA - ADR | 359,305 | $48.5M | 3.13% | — | |
| 10 | DBVTDBV Technologies SA | 2,461,626 | $47.2M | 3.05% | +1.4M | |
| 11 | SABSSAB Biotherapeutics Inc | 11,420,000 | $42.7M | 2.76% | — | |
| 12 | SLNOSoleno Therapeutics Inc | 894,909 | $41.4M | 2.68% | -1,383,294 | |
| 13 | DRUGBright Minds Biosciences Inc | 501,617 | $39.1M | 2.53% | — | |
| 14 | SVASinovac Biotech Ltd. | 5,903,000 | $38.2M | 2.47% | — | |
| 15 | GONGeron Corp | 27,225,292 | $35.9M | 2.32% | — | |
| 16 | ERASErasca Inc | 9,273,428 | $34.5M | 2.23% | — | |
| 17 | ZBIOZenas Biopharma Inc | 853,495 | $31.0M | 2.00% | -329,765 | |
| 18 | VRDNViridian Therapeutics Inc | 982,576 | $30.6M | 1.98% | — | |
| 19 | ACRSAclaris Therapeutics, Inc. | 8,888,888 | $26.8M | 1.73% | — | |
| 20 | CAMPCAMP4 Therapeutics Inc | 4,246,568 | $26.0M | 1.68% | +325K | |
| 21 | TNGXTango Therapeutics Inc | 2,154,780 | $19.1M | 1.23% | +1.4M | |
| 22 | ANROAlto Neuroscience Inc | 1,035,551 | $18.4M | 1.19% | NEW | |
| 23 | LBRXLB Pharmaceuticals Inc | 800,000 | $17.8M | 1.15% | — | |
| 24 | NERVMinerva Neurosciences Inc | 4,322,747 | $17.4M | 1.12% | NEW | |
| 25 | ORICOric Pharmaceuticals Inc | 2,118,384 | $17.3M | 1.12% | -1,008,220 |
Quarterly Changes
New Positions
Sector Breakdown
Healthcare0.0% ($2.1601596938852127e+199T)
Unknown0.0% ($21.1T)
Filing History
| Quarter | Filing Date | Portfolio Value | Holdings |
|---|---|---|---|
| Q4 2025 | Feb 13, 2026 | $1.5B | 47 |
| Q3 2025 | Nov 14, 2025 | $1.2T | 47 |
| Q2 2025 | Aug 14, 2025 | $977.1B | 42 |
| Q1 2025 | May 12, 2025 | $755.1B | 40 |
| Q4 2024 | Feb 13, 2025 | $892.6B | 40 |
| Q3 2024 | Nov 13, 2024 | $1208.3T | 43 |
| Q2 2024 | Aug 14, 2024 | $1082.5T | 42 |
| Q1 2024 | Apr 22, 2024 | $1272.6T | 42 |
| Q4 2023 | Feb 7, 2024 | $1221.3T | 47 |
| Q3 2023 | Nov 8, 2023 | $912.8T | 53 |
| Q2 2023 | Aug 14, 2023 | $1448.8T | 48 |
| Q1 2023 | May 15, 2023 | $1441.1T | 48 |
| Q4 2022 | Feb 13, 2023 | $868.5B | 48 |
| Q3 2022 | Nov 14, 2022 | $905.8B | 51 |
| Q2 2022 | Aug 15, 2022 | $995.9B | 49 |
| Q1 2022 | May 13, 2022 | $1.5T | 54 |
| Q4 2021 | Feb 11, 2022 | $1.7T | 55 |
| Q3 2021 | Nov 15, 2021 | $2.2T | 60 |
| Q2 2021 | Aug 16, 2021 | $2.3T | 59 |
| Q1 2021 | May 17, 2021 | $2.8T | 63 |
| Q4 2020 | Feb 16, 2021 | $2.2T | 59 |
| Q3 2020 | Nov 13, 2020 | $1.7T | 64 |
| Q2 2020 | Aug 14, 2020 | $1.4T | 54 |
| Q1 2020 | May 15, 2020 | $1.1T | 53 |
| Q4 2019 | Feb 13, 2020 | $1.4T | 49 |
| Q3 2019 | Nov 13, 2019 | $878.8B | 49 |
| Q2 2019 | Aug 13, 2019 | $1.1T | 46 |
| Q1 2019 | May 14, 2019 | $1.0T | 49 |
| Q4 2018 | Feb 13, 2019 | $783.1B | 45 |
| Q3 2018 | Nov 13, 2018 | $992.2B | 44 |
| Q2 2018 | Aug 10, 2018 | $776.1B | 40 |
| Q1 2018 | May 15, 2018 | $705.9B | 34 |
| Q4 2017 | Feb 9, 2018 | $466.9B | 30 |
| Q3 2017 | Nov 13, 2017 | $494.8B | 29 |
| Q2 2017 | Aug 2, 2017 | $397.1B | 26 |
| Q1 2017 | May 15, 2017 | $339.9B | 23 |
| Q4 2016 | Feb 14, 2017 | $300.4B | 24 |
| Q3 2016 | Nov 14, 2016 | $320.9B | 22 |
| Q2 2016 | Aug 15, 2016 | $366.2B | 23 |
| Q1 2016 | May 16, 2016 | $398.7B | 24 |
Fund Information
Vivo Capital, LLC is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $1.5B across 47 holdings. The largest position is Terns Pharmaceuticals Inc (TERN), representing 14.0% of the portfolio. Compared to the previous quarter, the fund opened 7 new positions and closed 7 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.